Immunovaccine is developing NIH-funded biodefense vaccines; HIV-resistant sex workers could aid vaccine development;

> Immunovaccine is collaborating with the NIH to develop DepoVax-based next-generation biodefense vaccines against threatening biological agents. Immunovaccine release

> BioDiem has licensed its live attenuated influenza virus to Chinese company Changchun BCHT Biotechnology for the Chinese private sector market. BioDiem release

> Medicago has received the fourth milestone payment of $3.56 million from the Defense Advanced Research Projects Agency for manufacture of its plant-expressed VLP vaccines. Medicago release

> Sex workers resistant to HIV could help researchers find a new route to an AIDS vaccine. Article

> Combining a PSA vaccine with a monoclonal antibody in prostate cancer did not increase adverse effects in a Phase I trial. Abstract

> OncoPep has signed an agreement with Dana‐Farber Cancer Institute to license its multi‐peptide therapeutic cancer vaccine technology. OncoPep release

> A U.S. hospital has started a clinical trial for a brain tumor vaccine. Article

> A vaccine shows potential to protect against bacterial infection of orthopedic implants. ORS release

And Finally... PaxVax has expanded its executive management team at C-level with a new COO, CTO and CSO. PaxVax release

Suggested Articles

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.